Results 81 to 90 of about 8,132 (145)
Cell Death and DiseaseTumor-infiltrating myeloid cells (TIMs) are pivotal cell populations involved in the immunosuppressive tumor immune microenvironment (TIME). However, there has been little success in large-scale clinical trials of myeloid cell modulators.
Da Huang +17 more
doaj +1 more source
Cancer Medicine, Volume 15, Issue 10, October 2026.Intravital imaging using MCP1‐FITC and dextran‐AF680 assesses macrophage targeting and polarization in murine 4T1 tumor models. Visualization of M1‐like and M2‐like macrophages and M1/M2 ratio quantification support evaluation of anti‐CD47 immunotherapy, highlighting the potential of macrophage‐targeted imaging for patient stratification and treatment ...
Minfeng Yang +6 more
wiley +1 more source
Cancer, Volume 132, Issue 19, 1 October 2026.Abstract Background This clinical trial sought to determine whether SL‐172154 could be combined safely and improve the efficacy of azacitidine (AZA) in patients with higher‐risk myelodysplastic syndrome (HR‐MDS) or acute myeloid leukemia (AML). Methods Dose escalation: doses of 1, 3, and 6 mg/kg SL‐172154 was evaluated as monotherapy or in combination ...
Naval G. Daver +24 more
wiley +1 more source
Development of Fully Human Antibodies Targeting SIRPα and PLA2G7 for Cancer Therapy
AntibodiesBackground: Macrophages play an important role in eliminating diseased and damaged cells through programmed cell death. Signal regulatory protein alpha (SIRPα) is a crucial immune checkpoint primarily expressed on myeloid cells and macrophages.
Seungmin Shin +4 more
doaj +1 more source
CNS Neuroscience &Therapeutics, Volume 32, Issue 10, October 2026.Following traumatic CNS injury, PANoptosis is activated in microglia and neurons, with microglia–neuron crosstalk serving as a key feature of this process. The PANoptosome sensors ZBP1 and NLRP12, together with the adaptor ASC, activate downstream executioner proteins to drive PANoptosis.
Zhusheng Feng +5 more
wiley +1 more source
Investigating CD8 T Cell Exhaustion in Chronic LCMV Infection by Flow Cytometry
Current Protocols, Volume 6, Issue 10, October 2026.Abstract CD8 T cells and the process of T cell exhaustion are central topics in both basic immunology and translational research, including clinical applications. Here, we provide a comprehensive, step‐by‐step guide to investigate CD8 T cells in murine in vivo lymphocytic choriomeningitis virus (LCMV) infection models.
Dominique Stark +5 more
wiley +1 more source
PLoS ONESeveral T cell immune checkpoint blockade therapies have shown initial successes in multiple cancers. However, significant issues remain, including tumor relapse, severe toxicities, and a lack of efficacy in most patients.
Keifer G Kurtz +10 more
doaj +1 more source
Clinical and Translational Discovery, Volume 6, Issue 5, October 2026.This review presents a framework for selecting Claudin 18.2 (CLDN18.2)‐directed treatment modalities in pancreatic ductal adenocarcinoma according to tumour antigen coverage and spatial distribution. Representative assessment at baseline and reassessment after progression can guide treatment adaptation over time.
Ruyu Tan +5 more
wiley +1 more source
Cell & BioscienceBackground macrophage-targeting therapy of ischemic disease has made progress in clinic trial. However, the role and underlying mechanism of pro-inflammatory or anti-inflammatory polarized macrophages in modulating ischemic diseases remain incompletely ...
Haiyi Liu +8 more
doaj +1 more source
Clinical and Translational Medicine, Volume 16, Issue 10, October 2026.Divergent triggering receptor expressed on myeloid cells 2 (TREM2) signalling pathways instruct myeloid cell adaptation towards neuroprotective disease‐associated microglia (DAM)/lipid‐associated macrophage (LAM) or immunosuppressive tumour‐associated macrophage (TAM) phenotypes.
Yaqing Lv +5 more
wiley +1 more source